within Pharmacolibrary.Drugs.ATC.L;

model L03AX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 2.5e-05,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.04,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L03AX02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Roquinimex (Linomide) is an immunomodulatory agent that was investigated for use in multiple sclerosis, certain cancers, and other autoimmune conditions. Due to serious cardiotoxicity and other adverse events, the drug development was halted and it is not approved or used clinically today.</p><h4>Pharmacokinetics</h4><p>No published studies with formal pharmacokinetic parameters (such as volume of distribution, clearance, bioavailability, or compartmental model) for roquinimex in humans are available. Estimated data based on chemical properties and limited preclinical summary reports.</p><h4>References</h4><ol><li><p>Strandgården, K, et al., &amp; Gunnarsson, PO (2000). Absorption and disposition including enterohepatic circulation of (14C) roquinimex after oral administration to healthy volunteers. <i>Biopharmaceutics &amp; drug disposition</i> 21(2) 53–67. DOI:<a href=&quot;https://doi.org/10.1002/1099-081x(200003)21:2&lt;53::aid-bdd214&gt;3.0.co;2-f&quot;>10.1002/1099-081x(200003)21:2&lt;53::aid-bdd214&gt;3.0.co;2-f</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11100907/&quot;>https://pubmed.ncbi.nlm.nih.gov/11100907</a></p></li><li><p>Strandgârden, K, et al., &amp; Gunnarsson, PO (1999). Dissolution rate-limited absorption and complete bioavailability of roquinimex in man. <i>Biopharmaceutics &amp; drug disposition</i> 20(7) 347–354. DOI:<a href=&quot;https://doi.org/10.1002/(sici)1099-081x(199910)20:7&lt;347::aid-bdd194&gt;3.0.co;2-0&quot;>10.1002/(sici)1099-081x(199910)20:7&lt;347::aid-bdd194&gt;3.0.co;2-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10760843/&quot;>https://pubmed.ncbi.nlm.nih.gov/10760843</a></p></li><li><p>Borgström, P, et al., &amp; Hartley-Asp, B (1994). The quinoline-3-carboxamide linomide inhibits angiogenesis in vivo. <i>Cancer chemotherapy and pharmacology</i> 34(4) 280–286. DOI:<a href=&quot;https://doi.org/10.1007/BF00686033&quot;>10.1007/BF00686033</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7518359/&quot;>https://pubmed.ncbi.nlm.nih.gov/7518359</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L03AX02;
